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Itch (pruritus) is a sensory phenomenon characterized by a (usually) negative affective component and the initiation of a special behavioral act,
i.e. scratching. Older studies predominantly have interpreted itch as a type of pain. Recent neurophysiological findings, however, have provided
compelling evidence that itch (although it indeed has intimate connections to pain) rather needs to be understood as a separate sensory modality.
Therefore, a novel pruriceptive system has been proposed, within which itch-inducing peripheral mediators (pruritogens), itch-selective receptors
(pruriceptors), sensory afferents and spinal cord neurons, and defined, itch-processing central nervous system regions display complex, layered
responses to itch. In this review, we begin with a current overview on the neurophysiology of pruritus, and distinguish it from that of pain. We then
focus on the functional characteristics of the large family of transient receptor potential (TRP) channels in skin-coupled sensory mechanisms,
including itch and pain. In particular, we argue that – due to their expression patterns, activation mechanisms, regulatory roles, and
pharmacological sensitivities – certain thermosensitive TRP channels are key players in pruritus pathogenesis. We close by proposing a novel,
TRP-centered concept of pruritus pathogenesis and sketch important future experimental directions towards the therapeutic targeting of TRP
channels in the clinical management of itch.
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1.1. Basic phenomenon — Itch is “created” by our brain
From a phenomenological point of view, itch (pruritus) can
be defined as an unpleasant cutaneous sensation associated with
urge desire to scratch, a more or less voluntary yet often sub-
conscious motor activity [1,2]. Hence, itch (as a “product” of the
central nervous system, CNS) [3,4] is clearly distinct from pain
with respect to not only the subjective sensation but also the
resulting motoric activities and behavioral patterns (e.g. pain-
related withdrawal reflexes) [5]. This suggests that the neuronal
“mechanism” for itch has developed as an evolutionarily ancient⁎ Corresponding author. Department of Physiology, University of Debrecen,
MHSC, 4032 Debrecen, Nagyerdei krt. 98., PO BOX 22, Hungary. Tel.: +36 52
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doi:10.1016/j.bbadis.2007.03.002system for the removal or avoidance of potentially harmful
agents (e.g. skin irritants, allergens, toxic plants) endangering
the integrity of the body. Itch-induced scratching can then be
interpreted as a goal-directed movement against noxious agents
that have successfully passed the epidermal barrier and have
already invaded the skin (where, against which, withdrawal
would make no sense).
1.2. Categories of itch
From a clinical point of view, pruritus is one of the most
common symptoms not only in dermatology, but also in general,
pediatric and geriatric medicine, and requires immediate and
effective therapy [2–8]. The importance of itch in general
medicine is evident e.g. in various malignancies (including
lymphoma, leukemia, and metastatic cancer), metabolic and
endocrine diseases (such as diabetes mellitus and thyroid
dysfunction), uremia, iron deficiency, generalized infection
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emotional stress, and in psychosomatic or psychiatric diseases
[2–9]. In short, “itch” is one of the central themes of medicine
and the life sciences.
Both clinicians and neurophysiologists, therefore, must be
able to differentiate between different types of pruritus. Given
that pruritus can be initiated by localized or systemic as well as
by peripheral or central stimuli (resulting in either localized or
generalized pruritus), the following itch categories have been
suggested, based on partly mechanism-based (i.e. neurophysio-
logically defined) and partly operational (i.e. clinically relevant)
definitions [2,4,9]:
➢ Pruriceptive itch: peripherally induced pruritus arising from
skin diseases such as dry skin, atopic dermatitis (AD),
psoriasis, infestations (e.g. scabies, pediculosis), urticaria.
➢ Neurogenic itch: centrally induced pruritus caused by
systemic disorders such as chronic liver disease (cholestasis),
chronic renal failure, thyroid dysfunction.
➢ Neuropathic itch: pruritus due to a primary neurological
disorder of the central or peripheral nervous systems, such as
it can be induced by certain brain tumors, multiple sclerosis,
peripheral neuropathy (e.g. postherpetic pruritus), nerve
compression or irritation (e.g. notalgia paresthetica, bra-
chioradial pruritus).
➢ Psychogenic itch: pruritus is related to psychological or
psychiatric disorders such as parasitophobia, obsessive–
compulsive disorder, leading to “neurotic excoriations”.
This review focuses on the first itch category (pruriceptive
itch), i.e. the characteristics of pruritus originating from the
skin.
1.3. Theories of itch
From a neurophysiological point of view, numerous
questions arise when one tries to define the exact mechanism
of itch among the plethora of distinct sensory physiological
phenomena. These include, for example:
➢ Is itch a type of pain, or just a “pain in the neck”?
➢ In other words, does pruritus “function” as a sub-modality of
pain or is it rather a separate sensory entity?
➢ Actually, what is the exact neurophysiological relationship
between itch and pain?
➢ Accordingly, do we really possess a specific sensory
pathway for itch, or does itch “use” defined elements of
the nociceptive system?
In order to properly answer these questions, it helps to begin
by systemically reviewing competing theories of itch.
According to the “intensity theory” of itch, low level
activation of nociceptors induces pruritus, whereas higher
stimulation rate provokes pain [10]. Following this theory, itch
represents quasi a submodality of pain and is based on a specific
pattern of action potentials running via nociceptive pathways;
hence, itch may result from the combination of other primarysensory signals [2,7]. However, application of low concentra-
tions of algogens generally does not cause itch, just less intense
pain, and stimulation of afferent nerves induces either pain or
pruritus. Moreover, increasing the stimulation frequency
elevates the intensity of pain or itch, but no transition from
one sensory modality to the other is recognized [5]. These
arguments clearly challenge the validity of the “intensity
theory”.
It is well known, however, that pain inhibits itch
[5,6,8,11,12]. Actually, the itch-induced scratching response,
in itself, is a motoric activity to induce pain and, hence, to
alleviate itch. This has encouraged the development of an itch
hypothesis that mirrors the “gate-control theory” of pain [8].
Indeed, numerous painful signals (such as noxious heat and cold,
mechanical, chemical or electrical stimuli) – via the activation of
specific nociceptive pathways and spinal cord as well as higher
CNS structures – have already been experimentally shown to
inhibit itch. This strongly suggests a central mode of action
[5,11,13–15]. Interestingly, certain agents that effectively
induce analgesia (e.g. μ-opioid receptor agonists) may indeed
reduce the inhibition of itch by pain, thus enhancing pruritus
[16,17]. Conversely, the application of μ-opioid antagonists (e.g.
to patients with cholestatic itch) can exert antipruritic effects;
however, the reduction of itch is accompanied by the induction
of pain [18] and withdrawal-like reactions [19]. It appears,
therefore, that besides similar patterns in sensation character-
istics, a definite antagonistic interaction does exist between itch
and pain.
Recent landmark findings have helped to establish a novel
hypothesis for the generation of pruritus; i.e. the “specificity or
selectivity theory” of itch [4], and introduced the novel pruri-
ceptive system dedicated for peripheral and central itch
processing. As detailed below, the pruriceptive system contains
specific as well as non-specific sensory afferents, itch-inducing
mediators (collectively referred to as pruritogens), and itch-
sensitive spinal projection neurons as well as higher CNS
structures. It is noteworthy, however, that the individual
components of the pruriceptive system are strikingly similar
(if not identical) to those of the classical, long-established
nociceptive system. This provides sound neurophysiological
explanations for the intimate relationship between itch and pain,
as delineated above.
1.4. The pruriceptive system
1.4.1. Pruriceptive primary afferent fibers
The skin is highly innervated with a dense network of
sensory afferents. Among the unmyelinated C-afferent axons
(also referred to as C-nociceptors), approximately 80% are
mechano-sensitive polymodal nociceptors, which respond to
mechanical, thermal (heat), and chemical stimuli [11,20,21].
The remaining approximately 20% do not respond to mechan-
ical stimulation (“silent nociceptors”) and are activated by
chemical stimuli [20,22].
Among the mechano-insensitive human C-fibers, a certain
subset of afferents (comprising approximately 20% of the
mechano-heat-insensitive class of C-fibers) has been discovered
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histamine (one of the most “popular” mediators of itch, see
below) in parallel to the itch ratings of human subjects [23–28].
However, the histamine-sensitive fiber subclass cannot account
for all aspects of itch, especially when pruritus is induced
mechanically or without the characteristic flare reaction (axon-
reflex erythema). Thus, other subgroups of primary afferents
(most probably mechano-heat sensitive ones) must be involved
in the generation of pruritus [29]. This diversity of afferent “itch
fibers” would nicely explain the various “submodalities” of
pruritus experienced by patients, similar to those of pain [30,31].
Nevertheless, these intriguing data strongly suggest that there is
a specific or – since pruriceptors also respond to capsaicin
and mustard oil, i.e. characteristic activators of mechano-heat
sensitive afferents (for details, see below) [32] – rather a highly
selective neuronal pathway for itch.
1.4.2. Spinal pruriceptive projection neurons and higher CNS
structures involved in central processing of itch
This concept has been further strengthened by the identifica-
tion of a distinct, histamine-responsive, and mechano-insensi-
tive class of dorsal horn (lamina I) neurons in the cat [12].
Importantly, the time course of these responses was perfectly
paralleled to that of itch sensation in humans. Interestingly, in
contrast to nociceptive second-order spinothalamic neurons, the
itch-specific projection neurons do not exhibit spontaneous
activity. It is proposed that the lack of spontaneous activity may
be generated by an active (tonic) inhibition exerted by pain-
processing neurons [11]. Therefore, suspension of the activity
of the “itch-inhibitory” nociceptive pathway might provoke
pruritus by a pure spinal mechanism — i.e. without any
activation of pruriceptive afferents of the skin (as seen e.g. in
neuropathic and neurogenic pruritus) [2–9].
The itch-selective spinal neurons form a distinct pathway
projecting from lamina I of the spinal cord to the ventrocaudal
part of nucleus medialis dorsalis of the thalamus which has
projections to higher CNS structures. The various sensory
components of itch have been therefore attributed to activation
of certain brain areas: the sensory-discriminative component in
the primary somatosensory cortex; the motor component of the
goal-directed scratching in the premotor and supplementary
motor cortex; the affective and motivational components in the
anterior cingulate [12,33–37] and insular cortex. Of great
importance, all these brain areas are also involved in pain
processing [38] suggesting that no clear-cut itch-specific CNS
centers exist. Thus, differences between central pain and itch
processing – such as the lack of activation of the secondary
somatosensory cortex areas and predominant activation of the
ipsilateral motor areas in itch – most likely result from a
different activation pattern of basically identical CNS centers
[36].
1.4.3. Pruritogens — Mediators of itch
As we have seen above, during the induction of pruriceptive
itch by defined noxi or skin diseases, the itch-selective afferent
fibers are stimulated by various chemical agents, collectively
referred to as pruritogens. These molecules are mostly releasedfrom various intracutaneous cell types which are in close
proximity to or even in direct physical contact with sensory
nerve endings [39,40]. The released pruritogens then are able to
stimulate and/or sensitize the itch-selective sensory afferents
resulting in action potential firing of the neurons and hence
initiating itch.
However, upon activation by noxious and/or pruritogenic
stimuli, certain neuropeptides (such as substance P [SP] and
calcitonin gene related peptide [CGRP]) are “anti-dromically”
released from cutaneous pruriceptors, which may act on
specific neuropeptide receptors expressed on a large variety
of non-neuronal cell types [39,40]. This serves to profoundly
modulate (i.e., mostly to further enhance!) the release of
pruritogens, thus generating (positive) regulatory loops. Hence,
the established bi-directional sensory neuron–non-neuronal
cell network lies at the central core of pruritus pathogenesis
[39–41].
In the following sections, we therefore shall briefly discuss a
(highly selected) list of pruritogens and their related prurito-
genic mechanisms (Table 1). The key message here is that the
“army” of itch-inducing agents appreciated to-date contains
many more pivotal players than the usual “suspect”, histamine;
and that these agents (not surprisingly at all, see above) are also
capable of inducing pain, depending on the actual peripheral or
central conditions [3]. However, due to the “extreme” over-
lapping of the nociceptive and pruriceptive systems, it is of
current debate whether (1) are there any pruritogens which have
no effect on the nociceptors; (2) can pruritogens activate
pruriceptors (without other stimuli) but only sensitize the
nociceptors; and (3) why do the below mediators sometimes
cause itch but sometimes cause pain?
1.4.3.1. Histamine. Although histamine is the best-known
pruritogen [42–44], its pivotal function in the pathogenesis of
itch is rather controversial. Endogenously, histamine is mostly
released from activated mast cells and epidermal keratinocytes,
and acts on specific H-receptors [39–41,45,46]. Accordingly,
histamine-induced skin reactions (the “classical triad” of itch,
wheal and flare) in humans were shown to be efficiently
prevented by inhibitors of histamine H1 receptors, also located
on sensory nerves [45,47]. However, small doses of histamine
that fail to produce itch are still sufficient to produce edema and
erythema upon intracutaneous injection. Furthermore, antago-
nists of the H1 (and/or H2) have often found ineffective as
antipruritic drugs, for example in the prototypic pruritic disease
AD [48].
Recently, however, additional H receptors have been
discovered, and at least one of them (H4) was shown to
function as an “itch receptor” in mice [49]. These latter data
encourages one to design new clinical trials to revisit the
relative importance of histamine in the pathogenesis of pruritus.
Similarly, further studies are required to clarify those findings
that H1 and H2 receptors, which are also expressed on
keratinocytes, were implicated in the regulation of epidermal
barrier [50], the dysregulation of which contributes to the
development of pruritus in dry skin conditions or in such
diseases as AD and psoriasis [6].
Table 1
Selected pruritogens and their effects a
Pruritogen Cellular action Source Functions related to itch
Acetylcholine Nicotinic and muscarinic
acetylcholine receptors
Nerves, epidermal keratinocytes,
lymphocytes, melanocytes
–Mediates itch in AD patients
Bradykinin Bradykinin (B1, B2) receptors Endothelial cells, immunocytes –Induces pain but also pruritus
–B2 receptor antagonists reduce itch
–Sensitizes sensory afferents for various
chemical stimuli (e.g. histamine)
–Pruritogenic in AD
Calcitonin
gene-related
peptide (CGRP)
CGRP-receptors Sensory nerve fibers –Induces pruritus intradermally
–Prolongs SP-induced itch latency injection
(inhibitory effect?)
–Increased CGRP in afferent fibers in itchy skin diseases
Endothelins Endothelin (ET) receptors Endothelium, mast cells –Induces burning itch
–Degraded by chymase via ETA-receptor activation
Histamine Histamine (H1–4) receptors Mast cells, epidermal
keratinocytes
–Induces itch via H1 in humans and also via H4 in mice
–In humans, H1 antagonists alleviate itch
–H1 and H2 receptors regulate epidermal barrier integrity
Interleukins (IL) IL receptors Immune cells –IL-2 induces itch in cancer patients
–IL-2 sensitizes sensory afferents
–Mice overexpressing IL-4 in the epidermis spontaneously
develop itch
–Elevated IL-6-like immunoreactivity was found in nerve
fibers of patients with prurigo nodularis
–Mice overexpressing IL-31 in T-cells develop itch
–IL-31 is increased in an atopic mouse model as well as
in AD
Leukotrienes Leukotriene receptor Mast cells, epidermal
keratinocytes
–Leukoriene B4 induces itch in mice
–Leukoriene B4 is involved in the SP- and
nociceptin-mediated induction of itch
NGF and
neurotrophins
(NT)
Specific receptors
TrkA : NGF
TrkB : NT-4
TrkC : NT-3
Epidermal and hair follicle
keratinocytes, fibroblasts,
mast cells
–NF, NT-3 and NT-4 acutely sensitize sensory afferents,
and up-regulate neuronal neuropeptides and TRPV1
–NGF and NT-4 are enhanced in AD
–NGF induces tryptase release from mast cells
–NGF and NT-4 induces sprouting of sensory afferents
resulting in chronic sensitization
Prostaglandins Prostanoid receptors Mast cells, epidermal
keratinocytes
–PGE1 and PGE2 potentiate the action of histamine
–PGE1 lowers itch threshold
–PGE2 evokes pruritus in AD
Proteases,
Kallikreins
Partly by proteinase-activated
receptors (PARs, tryptic enzymes)
Keratinocytes, endothelial
cells, mast cells, platelets
–Massive itch behavior in mice overexpressing epidermal
kallikrein 7
–Tryptase and PAR2 are increased in AD
–Tryptase induces inflammation and itch by a neurogenic
mechanism via PAR2
Substance P (SP) Tachykinin (neurokinin, NK)
receptors
Sensory nerve fibers –Primes and activates mast cells to release histamine
–Also induces the release of various pruritogens
(kinins, cytokines) from endothelial cells, keratinocytes,
and immune cells
a Listed in alphabetical order.
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pruriceptors induce the release of SP [23,51] which was
suggested to indirectly induce pruritus via the activation of non-
neuronal skin cells expressing cognate receptors. Indeed,
intradermal application of SP activates mast cells to release
histamine which, in turn, induces itch [42–44]. In addition, mast
cells can also release a plethora of (mostly) inflammatory
mediators which induce further liberation of SP from peripheral
nerve endings, leading to more mast cell activation [39–41,46].
SP may also trigger the release of other pruritogens from
various other cell types such as endothelial cells (kinins,endothelins), keratinocytes (nitric oxide), and immunocytes
(cytokines) [52–55] (see also next paragraphs).
In contrast, the role of the other main sensory neuron-derived
neuropeptide, CGRP, in the induction of itch is still rather
controversial. Namely, CGRP was shown to modulate itch and
inflammation [56,57]. In contrast, CGRP was found to prolong
SP-induced itch latency suggesting an inhibitory effect of
CGRP on SP-induced itching [58]. Interestingly, however,
increased levels of CGRP were found in nerve fibers of pruritic
diseases such as AD, nummular eczema [55], and prurigo
nodularis [59].
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sensitization of itch by arachidonic acid derivatives, kinins,
and interleukins. It has long been recognized that acute or
chronic inflammation of the skin sensitizes the nociceptive
sensory afferents resulting in inflammatory hyperalgesia [60]. It
was also known that numerous inflammatory mediators released
from mast cells (tryptase, tumor necrosis factor-α [TNF-α],
prostaglandins, leukotrienes), keratinocytes (prostanoids, nerve
growth fact [NGF] and other neurotrophins), endothelial cells
(kinins, endothelins), or immune cells (interleukins) also lower
the threshold for pruritic stimuli, and thus cause peripheral itch
sensitization [3,4,6,61]. These agents may trigger pruritus by
either binding to their specific receptors of the pruriceptive
sensory afferents or by inducing non-specific mechanisms
leading to elevated sensitivity of these neurons to other pru-
ritogens [62].
For example, prostaglandins (especially prostaglandin E1
and E2) were shown to potentiate histamine-induced itch
independently of the liberation of mast cell-derived histamine
[63,64]. In addition, pretreatment of human skin with pros-
taglandin E1 significantly lowered itch threshold [65] whereas
prostaglandin E2 evoked pruritus both in controls and in AD
patients [66]. Similarly, intradermal injection of another
eicosanoid, leukotriene B4 induced scratching in mice [67].
Furthermore, it was also suggested the SP-evoked itch (at least in
part) is due to the production prostaglandins and leukotrienes
[68].
The inflammatory mediator bradykinin (which induces pain
via activation of bradykinin B2 receptors located on the
nociceptors) can also induce itch [24,69,70]. Furthermore,
bradykinin induces the release of histamine from mast cells
[71]), augments the responses to subsequent histamine applica-
tion [72,73], and sensitizes sensory afferents for various
chemical stimuli [72]. Administration of bradykinin to the
skin also elevates the release of SP, CGRP, and prostaglandin E2
[56] hence may significantly amplify the activity of the
pruritogenic cellular network. Finally, a recent report has also
shown that bradykinin is a potent pruritogen in AD as well [74].
Certain members of the large family of inflammatory
immune cell-derived interleukins (IL) are also implicated in
the pathogenesis of pruritus. For example, recombinant IL-2
(administered to cancer patients) was shown to induce pruritus
[75]. Moreover, IL-2 induces itch by activation of a subpopula-
tion of cutaneous C-fibers that are chemosensitive to histamine
and bradykinin [76,77] suggesting that bradykinin may enhance
the itch-inducing effect of IL-2 [78]. Furthermore, transgenic
mice overexpressing IL-4 in the epidermis spontaneously
developed a pruritic inflammatory skin disease resembling
human AD [79]. Accordingly, elevated IL-6-like immunor-
eactivity was found in nerve fibers of patients with prurigo
nodularis [80]. In addition, it was demonstrated that transgenic
overexpression of the novel cytokine IL-31 in T-lymphocytes
induces severe pruritus and dermatitis in mice [81]. In good
accord with these data, expression of IL-31 was found to be
increased in an atopic mouse model [82] – as well as in patients
with AD [83] – and was shown to correlate to itch behavior
[84]. These results unambiguously argue for a special role forIL-31 in pruritus and that IL-31 and its signaling pathway may
represent a novel target for antipruritic therapy [85].
1.4.3.4. Proteases and their receptors. Serine proteases
(trypsin, chymotrypsin, chymase), generally regarded as “weap-
ons of (protein) mass destruction”, are capable of inducing
inflammation, pain, and pruritus [86–88]. Among their G
protein-coupled, metabotropic proteinase-activated receptors
(PAR) [89,90], PAR2 has been shown to play a key role in the
pathophysiology of itch [91]. Importantly, functional PAR2 is
expressed on sensory afferents which release neuropeptides
upon stimulation by tryptase [92,93]. With respect to itch, it was
also observed that the levels of the endogenous PAR2 agonist
tryptase as well as PAR2 were markedly increased on primary
afferent fibers of lesional skin of AD patients. Additionally,
keratinocyte-derived PAR2 was also upregulated in the epider-
mis of AD patients [94] and hence may mediate pruritus induced
by endogenous (trypsins, kallikreins) or exogenous proteases
(bacteria, house-dust mite). In perfect agreement with these
findings, intracutaneous injection of specific PAR2 agonists
provoked sustained and prolonged itch in such patients.
Moreover, inhibition of tissue kallikreine (tryptic enzyme)
suppressed itch [95] and kallikreine activity was also increased
in pruritic papular eruptions [96]. Since the concentration of
histamine was not changed in AD, these results suggest that the
activation of the novel protease-PAR2 pathway on cutaneous
sensory nerves might be more important than histamine for the
transmission of itch responses in AD (and probably in other skin
diseases).
1.4.3.5. NGF and certain neurotrophins — Acute and chronic
itch sensitizers. Neurotrophins (such as NGF and neurotro-
phin-4), which are produced and released by keratinocytes,
mast cells, and fibroblasts of the skin [97], were originally
described to play crucial roles in cutaneous nerve development
and regeneration [98]. It was also shown, however, that NGF
is highly overexpressed in inflamed and injured tissues and
that (as an inflammatory mediator) it initiates acute sensitiza-
tion and sprouting (leading to chronic sensitization) of C-type
afferent fibers via the activation of specific TrkA receptors
[98–101]. Indeed, NGF upregulates the expression of pru-
ritogenic neuropeptides (SP, CGRP) and certain receptors (e.g.
transient receptor potential vanilloid-1 [TRPV1], see below)
involved in itch, induces degranulation of mast cells, and was
found to be pruritogenic when administered therapeutically
[1,21,27,29,102,103,105]. In addition, serum levels of NGF
and SP were found to be increased in AD patients [104] and
these substances were shown to induce the release of the
pruritogenic mediator tryptase [97]. Also, mast cells and
keratinocytes produce high levels of NGF in AD which can be
stimulated by histamine [105]. Moreover, increased NGF
expression was detected in prurigo nodularis [106] and also in
pruritic lesions of patients with psoriasis [107], similarly to the
overexpression of neurotrophin-4 in lesional skin of AD
patients [108]. Taken together, these results are clearly in favor
of important roles of neurotrophins in the pathophysiology of
itching.
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2.1. Why TRP channels?
Recently, numerous lines of novel evidence suggest the
involvement of new “players” in the pathogenesis of pruricep-
tive itch. Among these, special attention has been attracted to
the transient receptor potential (TRP) superfamily [109–112],
especially to the thermosensitive ones [113]. Here is, why:
➢ As shown above, itch is a characteristic sensory modality
with specific/selective CNS processing → TRP channels
mostly function as “cellular sensors” of e.g. temperature,
osmotic concentration, and taste.
➢ Skin-originating itch requires an orchestration of bidirec-
tional sensory neuron — non-neuronal cell network→ TRP
channel are ideally suited to this task, since they are equally
expressed by both sensory neuronal structures and non-
neural cell types of the skin.
➢ The wide array of pruritogens may not only act on specific
receptors but also on various new, previously unappreciated,
targets→ such as the TRP channels.
➢ During the pharmacological treatment of pruritus, certain
agents may target novel molecules → such as the TRP
channels.
➢ As was revealed during anti-itch therapy using physical
methods, the itch pathway is clearly sensitive to temperature
changes→ such as numerous TRP channels.
On this background, the following paragraphs offer an
“exotic TRiP” to the fascinating, sometimes “cloudy”, yet
steadily unfolding “realm” of the TRP family, and discuss their
putative roles in itch pathogenesis. Along the way, we provide
novel perspectives on the potential use of TRP ligands in itch
management (Table 2).
2.2. TRPV1 — A thermosensitive channel with a central role in
the pathogenesis and therapy of itch
2.2.1. TRPV1 — A “hot and spicy” target of capsaicin on
sensory neurons
TRPV1, as key peripheral integrator of pain sensation, was
originally described on C-type nociceptive sensory neurons
[114,115] as a molecular target for capsaicin, the pungent
vanilloid ingredient of hot chili peppers [116]. The activation of
this non-specific cation channel (permeable to e.g. sodium and
calcium) first excites these neurons by initiating ionic fluxes and
concomitant action potential firing resulting in the induction of
pain in vivo [115,116]. Upon activation by TRPV1 agonists
(e.g. during capsaicin-treatment of the skin), these neurons
release their neuropeptide content (efferent function of the
sensory afferents, see above) which, by acting on the numerous
neighboring cell populations, leads to the initiation of
neurogenic inflammation [46,90,117]. Afterwards, prolonged
stimulation of TRPV1 induces desensitization (and, depending
on the actual concentration of the agonist, cell death) of thesensory afferents [114,115] which, at least in part, is due to
intracellular calcium accumulation and the depletion of
neuropeptides. Hence, prolonged TRPV1 activation results in
the suspension of the interplay between skin sensory neurons
and non-neuronal cells [2–4,6,8,9,114,115].
2.2.2. “Endovanilloids” — The “itch connection”
In addition to capsaicin, TRPV1 can also be activated and/or
sensitized by numerous endogenous substances collectively
referred to as “endovanilloids” [118]. The receptor was first
shown to be directly stimulated by low-threshold (>43 °C) heat
and acidosis [114]. Later, several other molecules were also
described to indirectly act on the TRPV1, i.e. via the activation
on their specific receptors and initiating various intracellular
signaling pathways. These stimuli are for example the
bradykinin [119,120], ATP [121], lipoxygenase products
[120,122], prostaglandins [123], histamine [124], various
neurotrophins (such as NGF, neurotrophin-3 and-4) [101,119],
TNF-α [125], pro-inflammatory chemokines [126], activation
of PAR2 by proteases [127,128] or activation of metabotropic
receptor-coupled hydrolysis of phosphatidylinositol 4,5-bispho-
sphate (PIP2) by phospholipase C (PLC) [129]. Most of the
above substances and mechanisms, released/activated chiefly
during inflammation, shift the activation threshold (>43 °C) of
TRPV1 (“to the left”) towards more physiological temperatures
hence leading to the acute or chronic sensitization of the
TRPV1-expressing nociceptive C-afferents (inflammatory ther-
mal “heat/hot” hyperalgesia) [115,130]. Taken together, these
findings imply that TRPV1 is indeed a central integrator
molecule in the pain pathway [115,131].
It is very important to note, however, the above endogenous
substances may not only act as algogenic chemical substances
but are also recognized as effective pruritogens (see in Table 1).
In addition, the itch-selective sensory afferents also respond to
the TRPV1-activator capsaicin suggesting that TRPV1 might
also be expressed on the pruriceptor subunit of mechano-
insensitive fibers [4]. Finally, it has also been shown that
increases in skin temperature or dysregulation of the pH of the
skin (another significant stimuli of TRPV1) can also effectively
modulate itch sensation in human [6,15,132]. Therefore, if one
takes a closer look to the above “special features” of TRPV1 in
relation to the neurophysiology of itch, one may also propose
that TRPV1 can also function as a “central integrator” molecule
in the itch pathway [3,6,8].
2.2.3. TRPV1 on non-neuronal cell types of the skin — Other
“itchy” findings to explore
Recent “hot” findings further highlighted the neurophysio-
logical importance of TRPV1 signaling in itch. Namely, TRPV1
channels were described on numerous non-neuronal cell types
[133–136] including, of greatest importance, human skin
epidermal keratinocytes, dermal mast cells, dendritic cells,
and various keratinocyte populations of the hair follicle [137–
143]. In addition, it was also proven that the activation of
TRPV1 – besides markedly affecting proliferation, differentia-
tion, and apoptosis – results in the release of such cytokines and
mediators (e.g. various ILs, prostaglandins, growth factors)
Table 2
Functions and potential therapeutic significance of thermosensitive TRP channels and their endogenous or exogenous modulators in itch
Receptor Expression in the skin Effects of endogenous modulators—physiological
role in itch
Effects of exogenous modulators — potential role
in the therapy of itch
TRPV1 –Sensory neurons
–Mast cells
–Sebocytes
–Epidermal
keratinocytes
–Hair follicle
keratinocytes
–Langerhans cells
–Smooth muscle
–Sebocytes
–Activated at T>43 °C and acidosis
–Activated/sensitized by pruritogenic substances
such as histamine, bradykinin, eicosanoids,
ATP, TNF-α, chemokines, prostaglandins, NGF,
neurotrophins, and tryptases
–Activated/sensitized by the PLC-dependent
hydrolysis of PIP2
–Also activated by the endocannabinoid anandamide
–Mediates inflammatory thermal “hot” hyperalgesia
–Regulates epidermal barrier integrity and homeostasis
–Capsaicin and RTX excites and then desensitizes
TRPV1 expressing sensory neurons resulting in depletion of
neuropeptides
–Capsaicin inhibits experimental and disease-related itch
–Camphor, which alleviates itch in pruritic diseases,
transiently activates then strongly desensitizes TRPV1
–Allicin, the pungent ingredient of garlic, activates TRPV1
–Noxious thermal stimuli (50 °C) inhibit histamine-induced itch
–TRPV1 activation by capsaicin affects epidermal and follicular
proliferation, differentiation, and apoptosis and release of
cytokines, ILs, and growth factors
–TRPV1 is increased in epidermal keratinocytes of prurigo
nodularis patients
TRPV2 –Sensory neurons –Activated at T≥52 °C –Noxious thermal stimuli (50 °C) inhibit histamine-induced itch
–Mast cells –Activation of TRPV2 on mast cells by thermal
stimuli results in a pro-inflammatory degranulation
event
TRPV3 –Sensory neurons
–Epidermal
keratinocytes
–Activated at T≥33 °C, also on epidermal
keratinocytes
–Sensitized by arachidonic acid and related
unsaturated fatty acids
–Augmented by histamine and bradykinin in a
PLC-dependent manner
–Eugenol, thymol, and carvacrol (from oregano, clove, and
thyme) activate and sensitize TRPV3
–Eugenol releases IL-1α from keratinocytes via TRPV3
–Camphor activates TRPV3
TRPV4 –Sensory neurons
–Epidermal
keratinocytes
–Mast cells
–Activated at T 27–42 °C
–Activated by anandamide and arachidonic acid via
the productions of lipid peroxidation products as
eicosanoids
–Regulates epidermal barrier integrity and homeostasis
–Not known
TRPM8 –Sensory neurons –Activated at T≤28 °C
–Metabotropic receptor-coupled hydrolysis of PIP2
inhibits its activity
–Menthol, eucalyptol, and icilin activate TRPM8 (and induce
sensation of cooling)
–Cooling, menthol, and icilin inhibit experimental or
disease-related itch
TRPA1 –Activated by bradykinin, arachidonic acid, and
prostaglandins
–Activated by a PLC-dependent mechanisms
–Its noxious (T≤17 °C) cold sensitivity is
controversial
–Its role in inflammatory thermal “cold”
hyperalgesia is controversial
–Allyl isothyocyanate (alkaloid of e.g. mustard oil, wasabi, and
horseradish) and cinnamaldehyde (substance isolated from
cinnamon oil) activates TRPA1
–Allicin, the pungent ingredient of garlic, activates TRPA1
–Carvacrol activates TRPA1
–Menthol inhibits TRPA1
–Camphor inhibits TRPA1
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induction of itch sensation [133–136,141–143].
These novel findings, therefore, invite an attractive hypoth-
esis: According to this, algogenic and pruritogenic substances
may therefore not only target TRPV1-expressing sensory
neurons but also e.g. TRPV1-expressing mast cells and
keratinocytes, and, hence, significantly modulate the proposed
neuronal–non-neuronal interaction network to initiate and
augment itch [3,6,8]. In fact, the importance of keratinocyte-
specific TRPV1 was strengthened by presenting that expression
of the receptor was dramatically increased in epidermal
keratinocytes of prurigo nodularis patients [141].
2.2.4. Therapeutic implications— The vanilloid-TRPV1 system
to mitigate itch
2.2.4.1. Capsaicin and related exovanilloids. The generally
accepted basis for the therapeutic application of capsaicin tomitigate pain and itch is the well-appreciated densensitizing
effect of this vanilloid [115,116,144,145]. Namely, prolonged
or repeated vanilloid application results in a depletion of
neuropeptides such as SP in the C-type neurons, hence sus-
pending the interplay between skin sensory neurons and other
cell populations of the skin [2–4,6,8,9,146]. Indeed, topical
capsaicin effectively prevents histamine-induced itch under
experimental conditions [147]. In addition, capsaicin cream
(0.025–0.075%) is widely used as an antipruritic agent in
several pruritic dermatoses, ranging from prurigo nodularis and
notalgia paresthetica via pruritus ani, to hemodialysis-related
and uremic pruritus, where a cascade-like augmentation of the
intercellular skin network “into a vicious itch circle” (which can
be effectively interrupted by capsaicin administration) is clearly
documented [2,9,144,146,148].
The most notorious clinical limitation of capsaicin applica-
tion is the TRPV1-coupled acute excitation of the sensory
C-afferents, which results in a marked burning sensation
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inhibits itch via central mechanisms, one might also speculate:
What if the effectiveness of capsaicin to terminate itch is (at least
in part) due to its (undesired) pain-inducing properties?
Unfortunately, systematic studies that address this intriguing
question have not yet been published (e.g. by measuring the itch
behavior of TRPV1-KO mice). Nevertheless, at least for now,
the need of repeated and prolonged capsaicin application
protocols (which fully deplete neuropeptide content of sensory
afferents) to efficiently alleviate itch [8,144,146,148] argues
against this hypothesis and suggest a peripheral action of
capsaicin in its function as an anti-itch agent.
Considering that pruritic patients usually poorly tolerate
capsaicin-induced pain, very often resulting in a greatly reduced
patient compliance [149], another important therapeutic
achievement, therefore, would be to find and/or synthetically
design such TRPV1 agonists which cause only minor receptor
excitation (i.e. pain), but still possess a significant desensitiza-
tion power (thus suppressing itch). Perhaps, the most promising
candidate to start-off this important search for better anti-
pruritic agents is resiniferatoxin (RTX), another natural product
of Euphorbia resinifera (a cactus-like plant) [116,117,150].
Intriguingly, this TRPV1 agonist exerts a threefold higher
potency to induce desensitization (i.e. to treat pain and
presumably itch) than excitation (i.e. to induce pain) [116].
Furthermore, future clinical trials should also systemically
analyze the in vivo effects of TRPV1 antagonists (such as
capsazepine or iodo-RTX) [151,152] to suppress itch.
2.2.4.2. Cannabinoids and TRPV1 — The challenge of getting
the skin “high”, rather than “itchy”. Another endogenous,
arachidonic acid metabolism-derived substance, anandamide
(N-arachidonoylethanolamine) connects TRPV1-mediated sig-
naling to the cannabinoids and their receptors (CB-R), another
very intriguing endogenous system for the modulation of both
pain and itch [153]. CB-Rs and TRPV1 show a marked co-
localization pattern on primary afferents [154–157]. On these
sensory structures, the stimulation of CB-Rs by various (endo-
and exo-) cannabinoids effectively inhibits pain [158,159] —
similar to the effects seen with TRPV1-mediated desensitization
(see above). The intimate relationship between the two systems
is also supported by the observation that the endocannabinoid
anandamide, depending on its concentration and other local
factors (such as e.g. acidosis in inflammation) [160], may also
stimulate TRPV1-mediated signaling (e.g. intracellular calcium
elevations) acting as an “endovanilloid” [118,153,158].
Various synthetic exocannabinoids, applied either intrader-
mally or topically, also effectively prevent both histamine-
induced [161] and disease-related [162,163] pruritus. Since this
effect is accompanied by a decreased neuropeptide release from
the sensory endings [161], this suggests that the TRPV1
pathway may also be involved in mediating the antipruritic
action of cannabinoids. Moreover, CB-R1 and CB-R2 have
recently been identified on epidermal keratinocytes, along with
numerous other non-neuronal cell types of human skin (in part,
in co-localization with TRPV1!) [157,164]. On keratinocytes,
the activation of CB-R2 resulted in the release of β-endorphin[165], an analgesic and antipruritic proopiomelanocortin
product. This suggests the involvement of CB-R-mediated
signaling in the neuronal–non-neuronal cellular networks that
generate itch.
Collectively, these finding strongly argue for that – just as
the TRPV1-coupled vanilloid system – the cannabinoid/CB-R
signaling mechanisms not only participate in nociception, but
also in the modulation of pruriception. If this concept is
corroborated by further experimental evidence, the co-admin-
istration of TRPV1 and CB-R agonists becomes another very
promising, novel pharmacological anti-itch strategy. This
approach would not only augment our anti-pruritic armamen-
tarium (to additively alleviate itch), but may also serve to
greatly reduce or even eliminate the ill-tolerated burning
sensation caused by capsaicin. As a support for this argument,
CB agonists have already been shown to prevent acute
excitation induced by the TRPV1 agonist capsaicin [166,167].
Alternatively, some CB agonists were shown to mildly activate
TRPV1 causing desensitization of the channel and hence
leading to a reduced activation by capsaicin [168].
2.2.4.3. Physical methods to target TRPV1 — “Burning itch
with fire”?. It is ancient knowledge among “pruritologists”
[2,4] that whereas cooling inhibits the itch sensation, warming
of the skin aggravates pruritus. Recent findings, however, seem
to challenge (at least in part) this popular paradigm. Namely,
Yosipovitch and coworkers [15] have shown that stimulation of
human skin by noxious thermal stimuli (close to 50 °C),
surprisingly, markedly inhibited the histamine-induced itch (and
hyperemia). Although the exact mechanism and its potential
therapeutic implications of this intriguing effect remain to be
determined, the phenomenon itself strongly suggests that
TRPV1 expressed on sensory neurons and/or non-neuronal
cells (as well as other noxious heat-activated TRP channels such
as TRPV2, see below) are directly involved in the antipruritic
efficacy of such a “thermal physiotherapy”.
2.3. Other thermosensitive TRP channels as novel players in
pruritus
The profound temperature-dependence of itch sensation has
also drawn attention to numerous other thermosensitive TRP
channels (besides TRPV1), which have recently been identified
as molecular sensors of temperature changes [109–113]. Each
of these distinct cellular temperature sensors, which belong to
the TRPV, TRPM, and TRPA subfamilies, is specialized to
detect well-defined temperature spectra (some are stimulated by
heat, others by cold), thus enabling the body to obtain
temperature “readings” over almost the entire relevant tem-
perature range faced by mammals [109–113].
2.3.1. TRPV2, TRPV3, and TRPV4— More “hot” is coming to
fight itch
Similar to TRPV1 (which is activated at ≥43 °C), the
TRPV2, TRPV3, and TRPV4 (originally described as an osmo-
sensor [169]) channels also function as cellular temperature
sensor molecules, since all are activated by increasing tem-
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In the context of skin-related sensory modalities, TRPV3
(activated at≥33 °C) [170–172] and TRPV4 (with an activation
range of 27–42 °C) [173,174] have attracted special attention.
However, the expression of these channels on sensory
neuronal structures is very controversially described in the
literature. Namely, whereas TRPV3 was clearly identified in
human and monkey dorsal root ganglia (DRG) [170,172], its
presence was not found in rat or mouse DRG [171]. In contrast,
TRPV4 was described in mouse DRG [169] and on free nerve
endings of mouse skin [175]. Moreover, in human and monkey
DRG, TRPV3 is expressed on the small diameter neuron
population (similar to TRPV4 in mouse DRG [175]), and, of
importance, in co-localization with TRPV1 [170,172]. In
addition, using a heterologous expression system, it was also
postulated that TRPV3 subunits form heteromultimeric struc-
tures by interacting with TRPV1 monomers and therefore may
act as signal co-transducers and/or regulators of TRPV1-
mediated signaling [170]. However, to further complicate this
issue, another group (using another expression system) failed to
identify homo- or heteromeric assembly of TRPV1 and TRPV3
subunits [176].
Of great importance, however, previous studies unambigu-
ously argue for that TRPV3 and TRPV4 are highly expressed in
skin epidermal keratinocytes [171,172,177,178], which, as was
detailed above, also express TRPV1 [137–141]. Moreover, it
was shown that these channels expressed by keratinocytes are
functional, since they mediate heat-activated membrane cur-
rents [177,178]. This is most strongly supported by the finding
that mice lacking TRPV3 have prominent deficits in their
response to both innocuous (mostly TRPV3 and TRPV4 range)
and painful heat (rather TRPV1 range) [179] — underscoring
the concept that TRPV3 is crucially involved in cutaneous
temperature sensation.
Although we possess only very limited data (see below) on
whether or not the activation of TRPV3 and TRPV4 results in
mediator release from keratinocytes (e.g. of pro-inflammatory
mediators, algogens, and pruritogens), the sensitivities of the
channels to certain chemicals and pharmacological agents
implicate their putative roles in the neurophysiology of itch.
Namely, several plant-derived skin sensitizers and allergens (and,
thus, potentially itch-inducing substances) that cause a “warm”
skin sensation (such as eugenol, thymol, and carvacrol — major
components of oregano, savory, clove and thyme) strongly
activate and sensitize TRPV3 [180]. In addition, the activation of
TRPV3 by eugenol on mouse keratinocytes results in the release
of (pro-inflammatory) IL-1α which may augment the skin-
sensitizing effect of this alkaloid [180].
It also deserves further consideration that the activities of
both channels (TRPV3, TRPV4) are potentiated by recognized
inflammatory pruritogens (similarly to the sensitization of
TRPV1, see above). Indeed, TRPV4 is activated by arachidonic
acid and its derivative, the endocannabinoid anandamide via the
generation of lipid peroxidation products such as eicosanoids
[181,182]. Similarly, TRPV3 is sensitized by arachidonic acid
and related unsaturated fatty acids [183], while the effects of the
culinary ingredients listed above are augmented by histamineand bradykinin in a metabotropic receptor-PLC-dependent
manner [180]. Moreover, both TRPV4 and TRPV1 (similar to
the pruritogenic histamine H1 and H2 receptors [52]) were
shown to play important roles in skin permeability barrier
homeostasis [184], the dysregulation of which represents a
major stimulus for the onset of itch [6].
In light of these data, it is of great clinical significance that
camphor (an aromatic and, when applied to human skin, mostly
pungent phytoproduct derived from the Cinnamonum cam-
phora tree) is a potent activator of TRPV3 [171,172,179].
Camphor has long been applied to alleviate itch in certain
pruritic dermatoses (such as contact irritant dermatitis) [185].
Interestingly, camphor also transiently activates TRPV1 (albeit
to lesser extent than capsaicin), but then strongly desensitizes
this vanilloid receptor thereby suspending the excitation of
TRPV1-expressing sensory afferents [186]. Moreover, camphor
also inhibits TRPA1 [187] which data collectively suggest a
possible synergistic interplay between TRPV1, TRPV3, and
TRPA1 to mediate the antipruritic (as well as analgesic) [188]
effect of camphor (see also below).
Finally, another heat-sensitive channel, TRPV2, deserves
mentioning. The molecule was first described on capsaicin- and
proton-insensitive, medium to large diameter primary nocicep-
tive sensory neurons and is activated by high-threshold
(≥52 °C) noxious thermal stimuli [189]. Keeping in mind the
key role of mast cells in the initiation of itch [3,40], it is
important to note that mast cells also express TRPV2 (along
with TRPV4 and TRPV1) [134,140,141,190]. Intriguingly, the
activation of mast cells by physical and thermal stimuli can
result in a pro-inflammatory degranulation event which depends
on the activity of protein kinase A-related signaling [190] —
one of the chief mechanisms in initiating the sensitization of
nociceptors and pruriceptors [123,191]! Furthermore, we have
already seen above that TRPV2 (besides TRPV1) may also
participate in mediating the antipruritic therapeutic effect of
noxious heat stimuli [15]. Clearly, further studies are urgently
needed to define the itch-related “non-thermosensor” roles of
these “hot” channels. However, taken together, the available
evidence already suggests that they closely resemble TRPV1
with respect to cell-specific expression (e.g. on sensory neurons
and various non-neuronal cell types of the skin), receptor
activation, sensitization, and signal transduction characteristics,
and warrant careful exploration in pathogenesis and clinical
management of itch.
2.3.2. TRPM8 — A “cool” anti-itch agent
TRPM8 is another thermosensitive member of the TRP
family [109–113]. In contrast to the heat-sensitivity of the
TRPV1–V4 channels, however, this calcium-permeable chan-
nel is activated by decreasing temperatures, down to the range
of innocuous (i.e. not painful) cold or coolness (≤28 °C)
[192,193]. Moreover, again in contrast to TRPV1 [129], the
metabotropic receptor-coupled hydrolysis of PIP2 inhibits the
activity of TRPM8 [194]. Consistent with these data, TRPM8 is
selectively expressed on a certain subpopulation of A and C-
type sensory afferents which is distinct from TRPV1-expressing
nociceptors [195]. Besides cooling, TRPM8 is highly activated
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[192,193,196]. These agents shift the activation threshold of
TRPM8 towards room temperature and, thus, sensitize the
TRM8-expressing sensory afferents. This induces the charac-
teristic “cool” sensation when these substances are applied to
the skin or mucosal surfaces.
In this context, it is important to recall that skin cooling
effectively inhibits itch, as has been demonstrated in numerous
trials [4,15,197]. Like physical skin cooling, menthol also
alleviates experimental [197] or disease-related [185,198,199]
pruritus. Importantly, menthol, besides stimulating TRPM8,
also inhibits TRPA1 [187] which may also contribute to its
effect to mitigate itch (see also below). Moreover, the super-
cooling agent icilin (which is 200–400 times more potent than
menthol in activating TRPM8) [192,196], when applied as 2%
ointment, reduced the degree of excoriations by 55%–60% in a
hairless rat model of scratching, provoked by a magnesium
deficient diet [8]. These findings strongly argue in favor of the
concept that TRPM8 offers an excellent target receptor for
mediating the antipruritic (as well as the analgesic) effects of the
above chemical and physical tools.
2.3.3. TRPA1 — A “pungent ic(e)ing on the cake”
TRPA1 was originally also described as a cold-sensitive,
calcium-permeable, non-selective cation channel [200], acti-
vated at the noxious cold temperature range (≤17 °C) [109–
113]. Recent findings, however, suggest that – based on its
localization, ligand sensitivity, and its relation to inflammation
– this “ice-cold” channel is more closely related to the “hot”
TRPV channels than to the “cool” TRPM8.
Namely, TRPA1 was found on TRPV1-positive sensory
nociceptive (and pruriceptive) afferents, yet not on the subset of
A and C-fibers which express TRPM8 (see above) [195,200].
Of further importance, pungent human skin irritants (i.e.
potential pruritogenic stimuli) such as allyl isothyocyanate
(alkaloids contained e.g. in mustard oil, wasabi, and horse-
radish, which induce skin pain and inflammation similar to the
TRPV1-activating capsaicin) and cinnamaldehyde (a substance
isolated from cinnamon oil) markedly and specifically activated
TRPA1 [201,202]. In addition, recognized algogenic and
pruritogenic inflammatory mediators such as bradykinin,
arachidonic acid, and prostaglandins as well as activation of
PLC were also shown to effectively activate TRPA1 [202]. This
must be expected to shift the activation temperature-threshold of
TRPA1 to more “physiological” temperature ranges — similar
to the effect seen with excitatory actions of these substances on
TRPV1, TRPV3, and TRPV4 (see above).
Therefore, in light of the above (i.e. TRPA1 was activated by
noxious cold and, at the same time, by agents causing pungent
“hot” sensation), Bandell et al. have proposed that TRPA1 may
serve as a molecular model explaining how noxious cold may
paradoxically cause painful burning [202]. In support of this
hypothesis, in animal models using either TRPA1-targeted
antisense or knockout technologies, it was shown that TRPA1
indeed participates in noxious cold sensation [203] and in the
development of cold hyperalgesia induced by either inflamma-
tion or nerve injury [204,205].Intriguingly, however, in parallel to the above studies, other
groups were unable to prove the (noxious) cold-sensitivity of
TRPA1 in cell cultures [201,206]. Similarly, Bautista et al. have
shown that TRPA1 knockout mice exhibit normal response to
cold stimuli [207]. However, these mutant animals displayed
pronounced deficits in nociceptor excitation and, of great
importance, in thermal pain hypersensitivity (heat hyperalgesia)
evoked by the inflammatory mediator bradykinin [203,207] —
similar to findings observed with TRPV1-deficient mice [130]! It
may be postulated, therefore, that algogenic and (since sensitiza-
tion also occurs for itch [3]) pruritogenic inflammation operates
as the common activation mechanism for TRPV1 and TRPA1
(and, quite probably, for other heat-sensitive TRPV channels, as
well). Indeed, using knockout animals, it was shown that both
TRPA1 and TRPV1 are required for the bradykinin-induced
thermal hyperalgesia [207] which, at the cellular level, involves
the stimulation of TRPA1 following activation/sensititation of
TRPV1 [207] or, alternatively, the sequential co-activation of the
two channels “the other way around” [168,208].
Naturally, further studies are to be performed to unambigu-
ously reveal the exact role of TRPA1 in temperature sensation
and the molecular and functional relationship of TRPA1 and
TRPV1. Nevertheless, the “exciting” complexity and contro-
versy of the “story” of above TRP channel may provide an
attractive explanation for how the distinct painful “cold” and
painful “hot” sensory modalities can travel alongside each other
so intimately.
2.3.4. Temperature-sensitive TRP channels establish a basic
syntax and molecular substrate of nociception and pruricep-
tion — The “molecular psychophysics” of itch and pain
sensation
The data presented above, on the one hand, clearly
demonstrate the potential neurophysiological roles of defined
temperature-sensitive TRP channels in the pathogenesis (and
possibly in the therapy) of pruritus. On the other hand, the
differential activation pattern of these molecules by various
skin-irritating agents may also help to understand the extreme
variability of sensations experienced by patients when such
substances are applied to human skin.
We propose that temperature-sensitive TRP channels estab-
lish a basic syntax and molecular substrate of nociception and –
due to the intimate relationship of pain and itch – for
pruriception, as well (Table 3). Following this novel working
hypothesis (which can also be referred to as the “molecular
psychophysics” of itch and pain sensation), these sensory
categories can, then, be distinguished and re-defined, which will
have to be taken into account when analyzing the pathogenesis
and management of itch:
➢ “Warm only” sensation (i.e. without pungency) — Stimuli
inducing a pure sensation of “warmth” (without any “burning
pain” component) may exclusively act on TRPV3 (and,
perhaps, also on TRPV4). The prototypic compound for such
sensation is eugenol (ingredient of clove oil), which selectively
activates TRPV3 without affecting the activity of other
thermosensitive TRP channels [180].
1014 T. Bíró et al. / Biochimica et Biophysica Acta 1772 (2007) 1004–1021➢ “Cool only” sensation (i.e. without pungency) — Stimuli
inducing a “pure coolness” sensation (without any “burning
pain” component) may exclusively act on TRPM8. Such a
compound is menthol which selectively activates TRPM8
[192,193,200]. However, it also inhibits TRPA1 [187] which
suggest that the “pure coolness” sensation induced by
menthol (via TRPM8) can be “fine-tuned” by eliminating
the “burning” component (via inhibiting TRPA1-mediated
signaling).
➢ “Painful burning” sensation (i.e. pungency) — Within this
category, based on experimental findings and on purely
theoretical speculations, the following subcategories can be
defined:
• It is well established that stimuli which may exclusively act
on TRPV1 (e.g. capsaicin) induce pungency with a charac-
teristic “hot” component (“Hot painful burning” sensation).
• Therefore, it would be feasible to propose that stimuli which
may exclusively act on TRPA1 would induce pungency
with a characteristic “cold” component. However, since the
“noxious” cold-sensitivity of TRPA1 is very controversially
described (see above) and, furthermore, since none of the
recognized TRPV1-acting agents such as allyl isothyocya-
nate and cinnamaldehyde induce cold sensation but rather
evoke “Hot painful burning”, the existence of the “Cold
painful burning” sensation is rather questionable.
• However, it is a common experience that allicin, the
pungent ingredient of garlic and capsaicin, the pungent
ingredient of hot chili peppers cause distinct pungent
sensations upon consumption (yet they both initiate
cutaneous irritation and edema). Namely, the ingestion of
garlic induces pungency without (or much less) char-
acteristic “hot” (or “cold”) component. Since allicin was
shown equally activate TRPA1 and TRPV1 [209,210], it
can be speculated that simultaneous activation of TRPA1Table 3
Temperature-sensitive TRP channels establish a basic syntax and molecular substrat
Prototypic agent Effect on TRP channels
Eugenol –Activates TRPV3
Menthol –Activates TRPM8
–Inhibits TRPA1
Capsaicin –Activates, then desensitizes TRPV1
Allyl isothyocyanate,
cinnamaldehyde
–Activates TRPA1
Allicin –Activates TRPA1
Carvacrol –Activates TRPV1
–Activates TRPV3
–Activates TRPA1
Camphor –Activates TRPV3
–Activates, then desensitizes TRPV1
–Inhibits TRPA1and TRPV1 would result in a different sensation
compared to those experienced upon selective involve-
ment of these channels. Therefore, an “Unspecified
painful burning only” sensation subcategory is proposed
for such agents and/or mechanisms which may co-
stimulate TRPV1 and TRPA1.
Naturally, “promiscuous” combinations of TRP channel
activation and/or inhibition by certain substances may result in
even more complex sensations, as they are sometimes reported
by patients [2,8]. An intriguing example for such a multimodal
(context-dependent?) inducer of itch/pain/burning sensations is
the spice-ingredient, carvacrol (contained in oregano) which,
besides activating TRPV3 (see above), also stimulates TRPA1
[180]. In perfect agreement with these cellular data, carvacrol,
when applied to the skin or mucosal surfaces, not only produces
“warm only” sensation but is also described as “pungent” and
painful [180].
In this complex framework of receptor-mediated sensations
under the “itch umbrella”, camphor is probably the “trickiest”
among the better-known, clinically long-employed compounds.
This skin irritant potently activates TRPV3 [171,172,179].
Subsequently, however, it first rapidly activates, and then
strongly desensitizes TRPV1 [186]. To add a further level of
complexity, camphor also inhibits TRPA1-mediated signaling
[186,187]. According to our “molecular psychophysics” hypo-
thesis introduced above, these mixed cellular effects on various
TRP channel targets may perfectly explain the in vivo sensation
“package” induced by skin-applied camphor; i.e. its ability to
induce “warm” (TRPV3 activation) as well as transient “burning
hot” (activation of TRPV1) sensations followed by the well-
known analgesia (desensitization of TRPV1 and inhibition of
TRPA1) [188]. Taken together, the presented “triple” mechan-
ism may also provide a rational molecular basis for the well-e (“molecular psychophysics”) of nociception and pruriception
Sensory phenomenon
–“Warm only” sensation (i.e. “pure warmness” without any
“burning pain” component)
–“Cool only” sensation (i.e. “pure coolness” without any
“burning pain” component)
–“Hot painful burning” sensation (i.e. pungency with a
characteristic “hot” component)
–Usually followed by analgesia
–“Hot painful burning” sensation (i.e. pungency with a
characteristic “hot” component)
–The existence of a “Cold painful burning” sensation is to
be determined
–“Unspecified painful burning only” sensation
(i.e. pungency without characteristic “hot” or “cold”
components)
Mixed sensation:
–“Warm only” sensation
–“Painful burning” sensation
Mixed sensation:
–“Warm only” sensation
–“Painful burning” sensation
–Followed by analgesia
1015T. Bíró et al. / Biochimica et Biophysica Acta 1772 (2007) 1004–1021documented efficacy of camphor to alleviate itch in certain
pruritic diseases (such as contact irritant dermatitis) [185].
Furthermore, it could also explain the great inter-individual
variations in a patient's response to cutaneous camphor
administration which might reflect constitutive differences in
the expression levels of and cross-signaling between distinct
TRP channels.
2.4. Other non-thermosensitive TRP channels — Distant
connections to pruritus
Although very little concrete information is as yet available
on these non-thermosensitive TRP channels, certain members
of the TRPC and TRPM subfamilies [109–113] can be
envisaged to contribute to the pathogenesis of pruritus.
2.4.1. TRPCs — Itch modulation via altered keratinocyte
differentiation?
TRPC channels are key regulators of intracellular calcium
homeostasis in a wide array of different cells types [109–113].
Importantly, numerous TRPC channels (TRPC1, TRPC4,
TRPC5, TRPC6, TRPC7) are expressed by epidermal or
mucosal keratinocytes [211–213]. Their expression levels
significantly fluctuate in a differentiation-dependent manner,
suggesting a role for these TRPC channels in the control of
keratinocyte differentiation [211–213]. Indeed, TRPC1 has
already been implicated in the calcium-induced terminal
differentiation of human keratinocytes in vitro [214].
Moreover, TRPC1 is overexpressed in epidermis of patients
with Darier's disease (DD) (or keratosis follicularis), a
genodermatosis which is induced by a genetic defect of the
sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2), and
which causes a severe, sometimes intensely pruritic epithelial
differentiation disorder [215,216]. TRPC1-mediated Ca2+ influx
is significantly higher in keratinocytes obtained from DD
patients. Furthermore, DD keratinocytes show enhanced
proliferation and apoptosis resistance, suggesting that TRPC1
is involved in the abnormal keratinization in DD epidermis.
Therefore, it is at least conceivable that a TRPC1-mediated
keratinization defect contributes to a – puritogenic! – disruption
of the epidermal barrier, and thus indirectly to itch pathogenesis.
2.4.2. TRPM6 and TRPM7 — Itch and the magnesium
connection
Finally, two channels of the TRPM subfamily (i.e. TRPM6
and TRPM7) may also affect itch pathogenesis. These
molecules are recognized as key regulators of cellular
magnesium homeostasis [109–113]. Since, in the rat, low-
dietary magnesium leads to lowered serum Mg2+, resulting in
universal dermatitis and intense scratching behavior [217], it is
tempting to ask whether a signaling dysfunction in the
“magnesium-controlling” members of the TRPM subfamily
can actually induce pruritogenic pruritus. That this line of
thought is not entirely speculative is suggested by the intriguing
clinical report that the pruritus of uremic patients completely
disappeared after decreasing the concentration of magnesium
Mg2+ in the dialysate [218].3. Conclusions, future perspectives
Here, we have reviewed pruritogenic stimuli, pruritogens
and selected neural elements and processing centers involved in
pruritus pathogenesis and the generation of the itch sensation.
Focusing on recent neurophysiological concepts that explain
pruriceptive pruritus and on the role of TRP channels in itch
pathogenesis, we have sketched the long path “pruritology” has
traveled to move, at long last, much closer to developing
intelligent combination strategies for more effective pruritus
management [3,4,6,8]. However, we still lack a single, easily
applicable, well-tolerated, and universally effective pharmaco-
logical ”itch killer”.
This underscores the vital clinical importance of identifying
novel candidate anti-pruritic agents that target defined
molecular itch pathogenesis pathways. In this review, our aim
was to specifically highlight the promise that individual
members of the fascinating TRP channel family hold in this
respect. Though the available information already has invited
the proposal of a novel molecular syntax of various itch-related
sensory qualities (which border on pain, warm, and cold
sensations or incorporate elements thereof), evidently, much
more extensive in vitro and in vivo studies are required to
explore the exact roles of TRP channels in the neurophysiology
and future therapy of itch.
Suffice it, therefore, we conclude this “exotic TRiP” into the
“dominion” of experimental, theoretical, and clinical “pruritol-
ogy” by defining a few “itchy frontiers” in pruritus research:
➢ Identification of physiological roles of TRP channels
expressed on non-neuronal cells of human skin during
inflammation and its related production of pruritogens.
➢ Definition of relationship of TRP channels to peripheral and
central itch processing (sensitization, desensitization).
➢ Determination of the expression patterns of individual TRP
channels in various pruritic dermatoses.
➢ Investigation of itch-related behavior of TRP channel gene-
deficient mice.
➢ In vivo evaluation of “combination therapies”, using
substances that target different TRP channels.
➢ Identification, synthesis, and in vitro as well as in vivo
evaluation of novel TRP-channel-acting pharmacological
agents, partly based on sensations defined by the concept of
“molecular psychophysics”.
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